To Read The Full Story
Continue reading your article with a Membership
Counsel
Dr. Reddy’s is being represented by Gopal Subramanium and Sai Deepak J, as well as a team at Sim and San: Mohit Goel, Sidhant Goel, Deepankar Mishra, Aditya Goel, and Kartikeya Tandon.
Meanwhile, Novo Nordisk is being represented by Inttl Advocare’s Hemant Singh, Mamta Jha, Siddhant Sharma, Rishabh Paliwal, Abhay Tandon, and Shreyansh Gupta.
Novo Nordisk’s global semaglutide patent enforcement campaign
Novo Nordisk has suffered a couple of recent blows in its global semaglutide patent enforcement campaign, including in the U.S., where the District of Delaware found its rival Viatris was not infringing one of five asserted patents (July 25, 2025 ip fray article).
Separately, in Canada, despite the country being home to the second-largest semaglutide market in the world (expected to grow at a rate of 22.9% between 2024 and 2030), and Ozempic being the largest revenue-generating product in that market (Grand View Research report), Novo Nordisk let one of its key Ozempic patents lapse (June 16, 2025 ip fray article).
However, the company did gain a victory in October, when it obtained, served, and enforced 29 preliminary injunctions (PIs) against (mostly Asian and to a lesser extent European) companies offering the active pharmaceutical ingredient semaglutide and/or pharmaceuticals containing semaglutide at the CPHI fair (October 31, 2025 ip fray article).